Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02045472 · ClinicalTrials.gov registry record · Phase 1

A Study of VIS410 to Assess Safety and Pharmacokinetics

A Phase 1 study of Influenza, sponsored by Visterra.

Completed
Registry status
Phase 1
Development phase
41
Enrollment target
1
Study location

NCT02045472 is a Phase 1 study of Influenza that has completed, run by Visterra. The registered enrollment target is 41 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02045472, a Phase 1 study of Influenza, has completed, sponsored by Visterra.

COMPLETED
Registry status
Phase 1
Development phase
41 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.

Conditions Studied

Influenza

Interventions

  • DRUG Placebo
  • DRUG VIS410

Study Locations (1)

Minnesota

  • DaVita Clinical Research - Minneapolis

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2014-09
Est. Completion 2015-05
Phase Phase 1

Sponsor

Visterra

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02045472

The ClinicalTrials.gov registry entry for NCT02045472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is Visterra, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02045472 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT02045472 about?

NCT02045472 is a clinical study titled "A Study of VIS410 to Assess Safety and Pharmacokinetics". The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacokinetics of single escalating doses of VIS410 in healthy volunteers.

What is the current status of trial NCT02045472?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2014-09. Estimated completion is 2015-05.

What conditions does trial NCT02045472 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT02045472?

The interventions under investigation include: Placebo (DRUG), VIS410 (DRUG).

Who is sponsoring clinical trial NCT02045472?

This trial is sponsored by Visterra, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02045472 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Influenza

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.